Zobrazeno 1 - 10
of 74
pro vyhledávání: '"C, Feierabend"'
Autor:
Minesh P. Mehta, Craig A. Schulz, Lori Hayes, Kim Binger, Rick Chappell, Dona Alberti, Rhoda Z. Arzoomanian, Keith A. Kunugi, C. Feierabend, H. Ian Robins, Cornelius J. McGinn, Timothy J. Kinsella, George Wilding, Kris Simon, Kendra D. Tutsch, Jen Volkman, Benham Badie
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 59:1107-1115
Purpose To investigate the maximal tolerated dose of a continuous 28-day iododeoxyuridine (IUdr) infusion combined with hyperfractionated accelerated radiotherapy (HART); to analyze the percentage of IUdr-thymidine replacement in peripheral granulocy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab53413f6e0e3f6d8f9607587b6c3982
https://doi.org/10.1016/j.ijrobp.2003.12.007
https://doi.org/10.1016/j.ijrobp.2003.12.007
Autor:
D. Alberti, Rebecca Marnocha, Katherine Oliver, Noelle K. LoConte, James P. Thomas, Jill M. Kolesar, Jens C. Eickhoff, Daniel Mulkerin, George Wilding, Kyle D. Holen, C. Feierabend
Background: A phase I study of high-dose capecitabine given over 2 days, along with oxaliplatin, bolus 5FU and leucovorin (LV), was designed to simulate FOLFOX6 without the need for infusional 5FU. Methods: Schedule A included oxaliplatin 100 mg/m2,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4c8501ebc47a2aaff3ddd37634ed3e7
https://europepmc.org/articles/PMC2899673/
https://europepmc.org/articles/PMC2899673/
Autor:
G H, Ripple, M N, Gould, R Z, Arzoomanian, D, Alberti, C, Feierabend, K, Simon, K, Binger, K D, Tutsch, M, Pomplun, A, Wahamaki, R, Marnocha, G, Wilding, H H, Bailey
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 6(2)
We conducted a phase I dose-escalation trial of perillyl alcohol (POH; NSC 641066) given p.o. on a continuous four times a day basis to characterize the maximum tolerated dose, toxicities, pharmacokinetic profile, and antitumor activity. Sixteen eval
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3a1c0d6db0b48760ae5c7c71abf51478
https://pubmed.ncbi.nlm.nih.gov/10690515
https://pubmed.ncbi.nlm.nih.gov/10690515
Autor:
C. Feierabend, David R. Spriggs, Mary Beth Tombes, George Wilding, Kendra D. Tutsch, Rhoda Z. Arzoomanian, Dona Alberti, H. Ian Robins
Publikováno v:
Investigational new drugs. 17(1)
Ormaplatin (NSC 363812, tetraplatin) is a stable platinum (IV) analog which has exhibited activity against cisplatin-resistant cell lines. A phase I trial of ormaplatin administered as a 1-h infusion every 4 weeks was performed. Forty-one patients re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::98223d1e440af6701184561d8617e27d
https://pubmed.ncbi.nlm.nih.gov/10555124
https://pubmed.ncbi.nlm.nih.gov/10555124
Autor:
H I, Robins, D M, Katschinski, W, Longo, E, Grosen, G, Wilding, W, Gillis, C, Kraemer, C L, Tiggelaar, D, Rushing, J A, Stewart, D, Spriggs, R, Love, R Z, Arzoomanian, C, Feierabend, D, Alberti, K, Morgan, K, Simon, F, d'Oleire
Publikováno v:
Cancer chemotherapy and pharmacology. 43(5)
To evaluate the feasibilitv of sequencing (based on preclinical modeling) tumor necrosis factor-a (TNF) at two dose levels with melphalan (L-PAM) and 41.8 C whole-body hyperthermia (WBH) for 60 min.Nine patients with refractory cancer were treated fr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d6a748ce185b1df7179755f75b7396bd
https://pubmed.ncbi.nlm.nih.gov/10100597
https://pubmed.ncbi.nlm.nih.gov/10100597
Autor:
Kendra D. Tutsch, Rhoda Z. Arzoomanian, Jordan Berlin, D. Alberti, Randall P. Rago, C. Feierabend, James M. Cleary, Paul R. Hutson, George Wilding
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 15(2)
PURPOSE We conducted a phase I trial of carboxyamidotriazole (CAI, NSC 609974), designed to determine the maximum-tolerated dose (MTD), toxicity profile, and pharmacokinetic characteristics of CAI gelatin capsule (gelcap) formulation administered dai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e73c79e858dbeddd66d8e1e3425c3db9
https://pubmed.ncbi.nlm.nih.gov/9053505
https://pubmed.ncbi.nlm.nih.gov/9053505
Autor:
C. Kraemer, Kendra D. Tutsch, D Paul, D. Alberti, R P Qu, D Rushing, Walter L. Longo, James A. Stewart, C. Feierabend, George Wilding, W. Gillis, David R. Spriggs, H. I. Robins, Kutz M, C L Tiggelaar, F. D'oleire, Rhoda Z. Arzoomanian
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 15(1)
PURPOSE To evaluate the biologic interactions and toxicities of melphalan (L-PAM) combined with 41.8 degrees C whole-body hyperthermia (WBH) for 60 minutes. PATIENTS AND METHODS Sixteen patients with refractory cancer were treated (May 1992 to May 19
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16a28ce3356309bae7eaf4c451d37471
https://pubmed.ncbi.nlm.nih.gov/8996137
https://pubmed.ncbi.nlm.nih.gov/8996137
Autor:
C J, McGinn, K A, Kunugi, K D, Tutsch, C, Feierabend, D, Alberti, M J, Lindstrom, G, Wilding, R Z, Arzoomanian, T J, Kinsella
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 2(8)
Evidence for clinically significant radiosensitization by the halogenated pyrimidine 5-iododeoxyuridine (IdUrd) continues to accumulate. In vitro radiosensitization has been demonstrated in human colon tumor cell lines following exposure to 1-10 micr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::234d498d22e5f6d2728da6d37a904c29
https://pubmed.ncbi.nlm.nih.gov/9816300
https://pubmed.ncbi.nlm.nih.gov/9816300
Autor:
Dona Alberti, Rhoda Z. Arzoomanian, Keith A. Kunugi, Minesh P. Mehta, Timothy J. Kinsella, H. I. Robins, C. Feierabend, Craig A. Schulz, George Wilding, Benham Badie, Kris Simon
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 39:139
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::27415e3f4da3412c5c2bcab3dbfe1eda
https://doi.org/10.1016/s0360-3016(97)80567-6
https://doi.org/10.1016/s0360-3016(97)80567-6
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.